Published in Drug Week, July 8th, 2005
The trials enrolled a total of 537 patients in 28 centers across the U.S. Patients in the study were administered either Oracea or placebo once a day for 16 weeks.
Dr. James del Rosso, clinical assistant professor, department of dermatology, University of Nevada School of Medicine, Las Vegas, Nevada, said: "With millions of patients seeking treatment for rosacea, it is exciting that the studies with Oracea...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.